Introduction: Standard practice in our unit is to take a group and save (G+S) blood sample for all patients undergoing a transurethral resection of prostate (TURP) and transurethral resection of bladder tumour (TURBT). Modern studies show the transfusion rates for TURP are 2%-7% and for TURBT 2%. Aims: We will determine how many patients undergoing TURP and TURBT required blood transfusion, analyse the indication, timing and risk factors. Additionally we will assess the cost effectiveness of routine G+S. Methods: A retrospective analysis was conducted between 1 March 2015 and 29 February 2016 (one year). Patients were identified from OPERA database and cross-referenced with blood transfusion records. Electronic case notes for patients receiving transfusions were reviewed. Results: A total of 167 patients underwent TURP. Of these, 0.6% (1/167) received transfusion on day 4 post-op. A total of 160 patients underwent TURBT. Overall 3.8% (6/160) received transfusion: three patients on days 0-1 and three patients on days 2-30. All patients had pre-op Hb <100 g/l. All had large muscle-invasive tumours. Cost in our lab of a G+S sample is £23.52. Two samples are now required before blood can be issued. Discussion: Our study shows that risk factors for transfusion are large prostates, likely muscle-invasive bladder tumours and pre-op Hb <100 g/l. Other risks include coagulopathy. These will usually be identified by the surgeon or pre-assessment clinic prior to the procedure. Change in policy would save money and time of phlebotomists and junior doctors. Conclusions: Routine G+S is not necessary for all patients. Patients with risk factors can be identified preoperatively. This would give a potential saving of over £15,000 per year. This can be implemented without adversely affecting patient safety.
Introduction
It is standard practice in many national and international centres to arrange group and save (G+S) ± cross-match before transurethral resection of prostate (TURP) and transurethral resection of bladder tumours (TURBT). Our local protocol states that G+S should be taken for all patients undergoing TURP and TURBT. There are currently no national guidelines on G+S; policies are made locally.
Blood transfusion rates in surgery overall have reduced by 20% since 2000 due to several initiatives. These include Better Blood Transfusion guidelines issued by the Department of Health 1 and subsequently the National Blood Transfusion Committee. 2 Measures include appropriate pre-assessment for planned procedures to allow identification and treatment of anaemia and optimisation of haemostasis during surgery. Most hospitals will have a local policy on blood transfusion and its indications and use alternatives where appropriate. Local minimal blood ordering schedule is in place in all hospitals and regular audit, such as this, guides protocol.
Historically, TURP or TURBT were associated with significant bleeding. 3 However, in recent years technical improvements such as continuous-flow resectoscopes and improved optics have resulted in a significant decrease in the risk of bleeding and blood transfusion. 4 The most up-to-date large meta-analysis of TURP complications has found that the rate of bleeding and transfusion has decreased with the development of better technology and technique. 4 Current transfusion rates for TURP are 2.0-7.0%. 4 TURBT transfusion rates are reported to be 2.3%. 5 Intraoperative haemodynamic instability warranting immediate transfusion is a rare event for both TURP and TURBT.
Risk factors for bleeding include large prostate gland or large bladder tumour and coagulopathy. These risk factors will usually be identified preoperatively by the surgeon and preoperative assessment clinic and so patients at high risk can be selected for G+S. We performed a retrospective, single-centre study with the aim to determine how many patients undergoing TURP and TURBT required blood transfusion, analysing the indication and timing of transfusion. Additionally we assessed the cost effectiveness of routine G+S for these patients.
Methods
Caldicott approval was granted by the Scottish National Blood Transfusion service. A retrospective analysis of patients undergoing TURP and TURBT between 1 March 2015 and 29 February 2016 (a 12-month period) was performed. We identified a total of 327 patients undergoing TURP (n = 167) and TURBT (n = 160). Patients were identified using the electronic OPERA theatre procedure database. This was then cross-referenced with blood bank records for G+S and whether any blood products were used. Patients who received a blood transfusion were identified and their individual risk factors were assessed by case note review.
Results

Blood transfusion rates -TURP
Among the 167 patients who had TURP, 89.2% (149/167) had G+S samples sent preoperatively. One patient required blood transfusion of two units on day 4 post-op for prolonged bleeding and dropping haemoglobin (Hb). This was a completion TURP of a large prostate. The patient had failed to void following removal of the catheter. He was not on finasteride preoperatively. The resected weight of tissue was 56 g and pathology was benign. The pre-op Hb was 131 g/l. Hence the TURP 30-day transfusion rate was 0.6% (1/167) ( Figure 1 ).
Blood transfusion rates -TURBT
Of the patients who underwent TURBT (n = 160), 91.3% (146/160) had G+S samples sent preoperatively. In this group, seven patients required blood transfusion within 30 days of surgery. There were three patients who received early post-op transfusions on day 0-1 post-op. These patients had large solid tumours and required transfusion both pre-and postoperatively. Their resections were incomplete and had extensive disease. All three had a preop Hb of <100 g/l.
There were three patients who received blood transfusions on days 2-30. One patient was an emergency admission with haematuria and required an urgent TURBT and bladder washout in theatre. This patient received a blood transfusion on day 7 post-op. One patient was admitted with haematuria and suspected urinary tract infection (UTI) 19 days post-TURBT. Another was readmitted 14 days post-op for pain and was transfused for low Hb secondary to extensive disease; this patient did not have haematuria ( Figure 2) . All of these patients had extensive muscle-invasive bladder tumours. All of these patients had a pre-op Hb of <100 g/l.
One patient received a blood transfusion during elective cardiac surgery 28 days post-op.
This gives our overall 30-day transfusion rate (excluding the elective cardiac surgery patient) for TURBT at 3.8% (6/160). All of the patients had extensive muscle invasive disease and were anaemic preoperatively (Table 1 ). 
Discussion
TURP and TURBT are some of the most commonly performed urological procedures. Our current local policy is for all patients undergoing a TURP or TURBT to have two G+S samples sent. At the time of this study only one sample was required. Our compliance with G+S samples was suboptimal (89.2% and 91.3%). This was likely due to human error and omission of taking the sample when the patient was admitted to the ward. In accordance with The British Committee for Standards in Haematology 6 recommendations, our hospital has implemented a second G+S sample policy. This improves blood transfusion safety but the indication for G+S is left to the individual hospital's blood transfusion service. We have shown that routine urology procedures (TURP and TURBT) are associated with low risk of transfusion. For TURP, this could be related to routine use of 5-alpha reductase inhibitors in our centre. These drugs reduce the size and vascularity of the prostate and hence the risk of bleeding. 7 Improved optics and resectoscopes have resulted in lower bleeding rates in recent years. 4 Current literature shows transfusion rates for TURP are 2.0%-7.1%. 4 This figure is higher than our results. Risk factors identified in the current literature include large gland size and coagulopathy. 4 Additional factors such as preoperative infection, urinary retention and prolonged resection times are also helpful in predicting need for blood transfusion. 4 As there was only one patient in the TURP group who received a transfusion, we cannot draw any definite conclusions about risk factors but can confirm that the rates of transfusion are very low.
Bladder cancer is the most common malignancy of the urinary tract and TURBT is regarded as the gold standard for the diagnosis and treatment of bladder tumours. 8, 9 TURBT covers a large range of tumour size and characteristics. A very tiny tumour would be considered a straightforward day-case procedure whereas a very extensive, solid muscle-invasive tumour would require a very different approach. These different characteristics can also increase risk of bladder perforation which increases the incidence of blood transfusion. 10 Investigations such as flexible cystoscopy and imaging prior to surgery will give the surgeon an estimate of the tumour size and this is performed in almost all cases. Modern studies have risk of bleeding 2.8% 11 and transfusion rates of around 2.3%-3.4% 5,11 with risk factors for transfusion being large-sized bladder tumours, low pre-op Hb and coagulopathy. 5 This is in keeping with our experience as most of the patients transfused in the TURBT group had large tumours and preop Hb <100 g/l. These factors can be identified pre-op and patients identified as 'high risk'.
Bleeding post-TURP or -TURBT can be early or delayed. In our audit, none of the patients required urgent transfusion. Patients requiring transfusion on day 0 or 1 post-op had already been receiving transfusions preoperatively. One of the anxieties that surgeons and anaesthetists have is how long it would take for blood to be available if needed urgently. In our lab, patients who have two samples sent preoperatively will have cross-matched blood ready in 5 minutes with electronic issuing. If a patient has one historical sample but no current second sample, a second sample should be taken and blood can then be issued within 20 minutes. If the clinical situation means there is no time for a second sample to be taken, then group-specific blood can be issued from a historical sample and takes around 30 minutes. In a life-threatening emergency O-negative blood is always available for immediate collection from the theatre fridge. Results of this audit are reassuring as emergency or urgent transfusion is an extremely rare event.
In our unit we have implemented a protocol to identify 'high-risk' patients who should have G+S samples sent preoperatively ( Figure 3) .
In our lab a G+S sample costs £23.52. Our hospital policy is to have two G+S samples taken from the patient preoperatively to improve safety. One of these samples may be a historical sample. Performing G+S samples adds further work for the phlebotomists and junior doctors. If these samples are not taken in a timely fashion, incorrectly labelled or if there are delays in transportation to the lab, patients may have their operation delayed. If we omitted G+S samples on the low-risk patients, this would result in a saving of up to £15,100 per year.
Conclusion
Our data are in keeping with current literature and demonstrate low rates of transfusion for TURP and TURBT. In view of these findings, it can be concluded that routine G+S is not required for all TURP and TURBT. High-risk patients should be identified preoperatively who have a coagulopathy, are on anticoagulants, have very large prostates, large bladder tumours or pre-op Hb <100 g/l. We believe that a change in policy would result in cost saving and reduced junior doctor and phlebotomists workload without adversely impacting on patient safety.
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